Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
The trimeric envelope glycoprotein spikes of HIV that mediate binding and entry are known to be susceptible to at least five major epitope classes of broadly neutralizing antibodies (bNAbs). Studies of these bNAbs and their epitopes, lineages, and maturation pathways are providing valuable insights for vaccine design (Mascola and Haynes, 2013) . In lieu of a vaccine, the isolated bNAbs as purified monoclonal antibodies (mAbs) are candidates for passive immunization to prevent HIV infection. Interest also exists in their potential use to treat established infection. Preliminary results in humans and animal models suggest the possibility of both uses (Caskey et al., 2015; Gautam et al., 2016; Lynch et al., 2015) . In this issue of Cell, two papers describe a major advance in achieving these goals: the development of synergistic antibodies with dual specificity that exhibit extraordinary potency and breadth of neutralization while preserving the normal architecture of IgG.
David Ho and colleagues (Huang et al., 2016) engineered their bispecific antibodies to pre-position at the cell surface and arrest the HIV at the site of entry ( Figure 1A ). Their best bispecific bNAbs combined one Fab from either an anti-CD4 or anti-CCR5 mAb, linked to another Fab derived from the gp41-specific bNAb, 10E8. Jeffrey Ravetch and colleagues (Bournazos et al., 2016 ) took a different approach and combined Fabs from two different bNAbs, one to the CD4 binding site of gp120 (3BNC117) and another to a gp120 V3-glycan epitope (PGT135) using an engineered hinge domain version of IgG3. Their goal was to crosslink two adjacent gp120 molecules in a trimer spike, thereby increasing antibody avidity while facilitating spike inactivation ( Figure 1B ). Both classes of bispecific antibodies performed far better than the combined activity of the individual parent antibodies in a striking display of synergy. This synergistic activity was superior to the best known bNAbs and rivaled the combined activity of up to five bNAbs.
Individual bNAbs tested in combination typically produce additive effects, with only weak synergism occasionally observed (Kong et al., 2015; Wagh et al., 2016) . The magnitude of synergism seen with the new bispecific bNAbs is quite remarkable by comparison. Engineering these bispecific antibodies to exhibit such potent synergism required persistent efforts. Many early constructs either lacked synergy or were less potent than the combined activity of the individual antibodies. Success was achieved through trial and error in an innovative series of experiments. Key insights were gained along the way that should facilitate additional synergistic bispecific bNAbs in the future.
These new bispecific bNAbs still need to pass the test of scale-up manufacturability, acceptable safety, tolerability and pharmacokinetic properties and lack of potential to elicit deleterious and potentially harmful anti-bispecific antibodies. Safety will be an especially critical test for bispecific bNAbs that target host CD4 and CCR5. Additional improvements in both classes might be possible by optimizing their interaction with the neonatal Fc receptor to prolong their serum halflife, increase mucosal localization, and provide longer-acting protection (Gautam et al., 2016; Ko et al., 2014) . Recombinant adeno-associated virus (AAV) vector gene delivery is another option that might be explored for long-term antibody persistence (Deal and Balazs, 2015) . Finally, though both classes of bispecific antibodies might prove powerful in preventing infection, their use for treatment faces the daunting challenge of impeding escape. All known bNAbs have associated viral resistance mutations. As with highly active antiretroviral drugs, potent and sustained control of the virus may require a combination of bNAbs that simultaneously target multiple sites of action, in this case different epitopes. In vitro predictions of the best existing three and four bNAb combinations suggest limitations in simultaneously targeting more than two epitopes on a majority of viruses (Wagh et al., 2016) . Combinations of synergistic bispecific bNAbs might afford advantages to overcome these limitations. The two lead candidates described above are interesting examples that together encompass four non-overlapping epitopes on gp120, gp41, and cell receptor molecules that would not be expected to exhibit crosscompetition.
Only a small number of bNAbs were known prior to 2009: these early bNAbs provided hope that such antibodies could be elicited by vaccination. They also served as a blueprint for immunogen design. As technologies improved and a new generation of bNAbs with superior neutralization potency and breadth was discovered, interest grew in the potential use of passive bNAbs for HIV prevention and treatment. The outstanding activity of the new synergistic bispecific bNAbs, together with early indications of favorable manufacturability and pharmacokinetic properties, brings us closer to achieving this goal.
The notion that the colon's deep crypt pockets provide a protected location that shields stem cells from potentially toxic substances is widely accepted. In this issue of Cell, Kaiko et al. reveal how a metabolite abundantly produced by the gut microbiota can inhibit stem cell proliferation but is blocked from doing so by crypt architecture.
The colonic epithelium is organized as a flat surface epithelium with highly repetitive invaginations known as crypts of Lieberkü hn. Actively proliferating colonic stem cells are located at the very bottom of these crypts and fuel the self-renewal of the epithelium. Fully differentiated colonocytes cover the flat surface of the colon and are continuously replaced by new generations of cells that exit the crypt pockets. Despite detailed knowledge about developmental signaling pathways that regulate stem cell positioning, function, and number (Barker, 2014) and the role of the colonic epithelium in maintaining a barrier against potentially harmful microorganisms and toxins (Garrett et al., 2010) , mechanistic insights into the complex interactions between gut microbes and colonic tissue has so far lacked behind.
In this issue of Cell, Kaiko et al., (2016) investigate how primary colon organoids that are enriched for highly proliferative stem/progenitor cells are influenced by a previously identified set of metabolites produced by the commensal gut microbiota and that are commonly found in the colonic lumen of mice (Matsumoto et al., 2012) . Butyrate-a product of dietary fiber fermentation-had the most significant negative effect at physiological
